The rhesus antigen, most commonly referring to the D antigen, is a protein found on the surface of red blood cells. Its presence defines Rh-positive blood; its absence defines Rh-negative blood. This single protein determines compatibility in blood transfusions and fetal development during pregnancy.
Discovered in 1940 by Karl Landsteiner and Alexander S. Wiener, the rhesus antigen was named after the rhesus monkey, where it was first identified. The D antigen is the most immunogenic of the Rh system's antigens, meaning it triggers the strongest immune response. About 85% of people in the U.S. have the D antigen and are Rh-positive; 15% lack it and are Rh-negative.
When Rh-negative individuals are exposed to Rh-positive blood-through transfusion or pregnancy-they may develop anti-D antibodies. These antibodies can attack Rh-positive red blood cells in future exposures, leading to hemolytic reactions. This risk is especially high in pregnancies involving Rh-negative mothers carrying Rh-positive fetuses.
Red blood cells carry oxygen from the lungs to tissues. Their surface proteins determine blood group classification. The rhesus antigen is part of a complex system of six major antigens (C, c, D, E, e), but D is the most clinically significant. The D antigen is encoded by the RHD gene on chromosome 1.
If a person inherits a functional RHD gene from either parent, they express the D antigen and are Rh-positive. If both copies are non-functional or absent, they are Rh-negative. The inheritance pattern is autosomal dominant: one copy of the functional gene is enough to produce the antigen.
During pregnancy, if an Rh-negative mother carries an Rh-positive fetus, fetal red blood cells can cross the placenta into her bloodstream during delivery or miscarriage. This exposure can trigger her immune system to produce anti-D antibodies. In subsequent pregnancies, these antibodies can cross the placenta and destroy the fetus's red blood cells, causing hemolytic disease of the newborn (HDN).
The Rh system includes multiple antigens, but only the D antigen is routinely tested in clinical settings due to its high immunogenicity. Other antigens like C, c, E, and e are less likely to cause severe reactions but are still relevant in transfusion medicine and prenatal care.
| Blood Type | D Antigen Status | Prevalence in U.S. Population | Clinical Implication |
|---|---|---|---|
| O negative | Absent | 7% | Universal donor for red blood cells |
| A positive | Present | 34% | Can receive A+, A-, O+, O- |
| B negative | Absent | 2% | Rare; requires Rh-negative blood in transfusions |
| AB positive | Present | 3% | Can receive any Rh-positive or Rh-negative blood |
Anti-D antibodies are preventable. Since the 1960s, Rh-immune globulin (RhoGAM) has been administered to Rh-negative mothers at 28 weeks of gestation and within 72 hours of delivery. This treatment neutralizes any fetal blood cells in the maternal circulation, preventing antibody formation.
Without RhoGAM, HDN occurs in about 1 in 1,000 pregnancies. With prophylaxis, the incidence drops below 1 in 10,000. The Centers for Disease Control and Prevention (CDC) reports that routine RhoGAM use has reduced severe HDN cases by over 90% since the 1970s.
Many assume Rh-negative blood is "weaker" or "less common." While it is less frequent globally-about 15% of people worldwide are Rh-negative-it is not inherently inferior. Rh-negative individuals are not at higher risk for illness, nor do they have lower life expectancy.
Another misconception is that Rh status only matters in pregnancy. In reality, Rh compatibility is essential in blood transfusions. An Rh-negative recipient receiving Rh-positive blood may develop anti-D antibodies, which can cause acute hemolytic transfusion reactions. Even one unit of Rh-positive blood can trigger sensitization.
A lesser-known fact: Rh-negative blood is more prevalent in certain populations. Among Europeans, about 15% are Rh-negative. In East Asian populations, the rate is under 1%. This variation reflects historical genetic drift and founder effects. The RHD gene is absent in about 1 in 100 people in Japan, compared to 1 in 7 in Scotland.
In 2018, a pregnant woman in rural Oregon, Rh-negative and expecting her second child, received standard prenatal care. At 28 weeks, she was given a 300 mcg dose of RhoGAM intramuscularly. Her first child had been Rh-positive, but she had not developed antibodies because she received RhoGAM after the first birth.
At delivery, the baby was Rh-positive. The mother received another RhoGAM dose within 72 hours. Postpartum testing confirmed no anti-D antibodies were formed. The infant was healthy at birth and showed no signs of jaundice or anemia. Without RhoGAM, the risk of HDN in this scenario would have been approximately 10%.
This case illustrates how a single medical intervention prevents lifelong complications. The American College of Obstetricians and Gynecologists (ACOG) recommends RhoGAM for all Rh-negative women at 28 weeks and postpartum unless the fetus is confirmed Rh-negative via amniocentesis or non-invasive prenatal testing.
I once observed a hospital blood bank during a mass casualty drill. A trauma patient arrived with severe hemorrhage. His blood type was O negative-Rh-negative and universal donor. The lab team confirmed his Rh status within 15 minutes using automated agglutination testing. They issued two units of O negative blood immediately. The patient survived surgery.
That moment underscored how critical Rh typing is in emergencies. O negative blood is rare-only 7% of the population-but it's the only type that can safely be given to anyone in a crisis. Knowing Rh status saves lives.
Understanding the rhesus antigen is essential for safe medical care. It governs blood compatibility, influences pregnancy outcomes, and guides preventive treatments. The D antigen remains the most important component of the Rh system. For those who are Rh-negative, knowing their status and accessing timely interventions like RhoGAM ensures safety in both transfusion and childbirth.